<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002621</url>
  </required_header>
  <id_info>
    <org_study_id>9362</org_study_id>
    <secondary_id>POG-9362</secondary_id>
    <secondary_id>CDR0000063972</secondary_id>
    <nct_id>NCT00002621</nct_id>
  </id_info>
  <brief_title>Interferon Alfa in Treating Children With HIV-Related Cancer</brief_title>
  <official_title>A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children&#xD;
      with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete response rate and one-year disease free survival of pediatric&#xD;
           patients with HIV-related malignancies treated with interferon alfa.&#xD;
&#xD;
        -  Determine the toxicity of interferon alfa alone and in combination with antiretroviral&#xD;
           therapy in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Induction: Patients receive interferon alfa subcutaneously (SC) daily on days 1-14.&#xD;
           Patients with advanced stage III or IV undifferentiated lymphomas or B-cell acute&#xD;
           lymphoblastic leukemia also receive hydrocortisone intrathecally (IT) combined with&#xD;
           cytarabine IT on day 14.&#xD;
&#xD;
        -  Maintenance: Patients with stable or responding disease after completion of induction&#xD;
           receive interferon alfa SC 3 times a week beginning on week 1. Treatment continues for a&#xD;
           minimum of 4-12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
           Patients who received IT therapy during induction receive the same IT therapy at 4, 8,&#xD;
           and 12 weeks and then every 8 weeks thereafter.&#xD;
&#xD;
      Patients are followed every 6 months for 4 years and then annually for survival until entry&#xD;
      on another POG protocol.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 evaluable patients will be accrued for this study within&#xD;
      4.2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate for HIV related malignancies treated with interferon</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Alpha interferon (aIFN) treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <arm_group_label>Alpha interferon (aIFN) treatment</arm_group_label>
    <other_name>Intron A</other_name>
    <other_name>Roferon A</other_name>
    <other_name>NSC 377523</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven malignancy diagnosed at any time following confirmation of&#xD;
             HIV-positivity, including the following:&#xD;
&#xD;
               -  Leukemia&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma&#xD;
&#xD;
               -  CNS lymphoma&#xD;
&#xD;
               -  Other solid tumors&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Concurrent registration on protocol POG-9182 required&#xD;
&#xD;
               -  Confirmed HIV-positive by POG-9182 criteria&#xD;
&#xD;
               -  Required biology studies completed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 4 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (unless bone marrow involvement present)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  SGPT and SGOT less than 2 times normal (may discuss with Study Coordinator)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Adequate cardiac function by echocardiogram/MUGA scan&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Chronically infected patients must be stable enough to meet life expectancy&#xD;
             requirement&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior interferon for cancer&#xD;
&#xD;
          -  Prior interferon alfa for viral infections (i.e., hepatitis) must be discussed with&#xD;
             Study Coordinator&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 week since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 week since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior antiretroviral therapy allowed&#xD;
&#xD;
          -  At least 1 week since prior acute treatment for any serious or life-threatening&#xD;
             infection&#xD;
&#xD;
          -  No concurrent local treatment unless discussed with the Study Coordinator&#xD;
&#xD;
          -  No concurrent acute treatment for any serious or life-threatening infection&#xD;
&#xD;
          -  Concurrent antiretroviral therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V. M. Whitehead, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Montreal Children's Hospital at McGill University Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomorrows Children's Institute</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Saint Joseph's Health System</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Pediatric Cancer and Blood Disorders Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico School of Medicine Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Pediatrie</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2003</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

